Effects of an Opiod Sparing Care Pathway for Patients undergoing Obesity Surgery

Effects of an Opiod Sparing Care Pathway for Patients undergoing Obesity Surgery - OS-PCC study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-003830-97-SE

Enrollment

220

Registered

2017-12-07

Start date

2018-02-19

Completion date

Unknown

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

See below MedDRA version: 21.1 Level: LLT Classification code 10059610 Term: Obesity surgery System Organ Class: 100000004865

Interventions

Trade Name: Dexdor Pharmaceutical Form: INN or Proposed INN: DEXMEDETOMIDINE CAS Number: 113775-47-6 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: See below Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 200 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: See below

Design outcomes

Primary

Measure	Time frame
Main Objective: See below;Secondary Objective: "Not applicable";Primary end point(s): See below;Timepoint(s) of evaluation of this end point: See below	—

Secondary

Measure	Time frame
Secondary end point(s): See below;Timepoint(s) of evaluation of this end point: See below	—

Countries

Sweden

Contacts

Public ContactSven-Egron Thörn

Sahlgrenska University Hospital

svenegron.thorn@vgregion.se46313434903

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026